PARIS, May 26, 2010 /PRNewswire/ -- CID Vascular, a leader in interventional medicine, is sponsoring Tech News Trends at Euro PCR on May 26th in Paris. The two-hour session will explore issues surrounding the complex decisions doctors must make when implanting coronary stents in patients with conditions that affect blood clotting.

Two live cases performed by Drs. Antonio Colombo and Giuseppe De Luca will be beamed by satellite from Milan, into the convention hall in Paris for viewing by doctors attending the meeting. Placing a stent in patients with coronary heart disease is just the beginning of their treatment. These patients need careful screening for the appropriate strategy to be applied, which includes device and drug therapies that optimize clinical outcomes. This is especially difficult in patients who cannot easily tolerate the medicines that are usually given for up to a year or more following a procedure, said Dr. Colombo of San Rafaelle Hospital, Milan, Italy.

The Optima Jet, drug-eluting stent with its Carbofilm coating and abluminal reservoir technology, has been selected for patients with a high risk of bleeding and the AvanteGarde due to its anti-thrombogenic properties for patients with high risk of thrombosis. We create our stents knowing that they must continue to provide patients with the best results and safety throughout their lives and we are very proud of our track record, said Franco Vallana, Chief Executive Officer of CID Vascular.

For more information on CID Vascular: http://www.cidvascular.com

SOURCE: CID Vascular

CONTACT: For more information on CID Vascular contact:Info@cidvascular.com, +39-0161-487338